Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers

Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers

US Patent 10954305 · Granted Mar 23, 2021

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Systems and methods for hemoclip deployment2025
Tool for hemostasis and tissue approximation2025
Anti-glare layer and manufacturing method thereof2025
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and de2025
Antibody-drug conjugates and uses thereof2025
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and de2025
Display device2024
Reflective active device array substrate and manufacturing method thereof and re2024
Display apparatus2023
Display device2023
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and de2023
Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy2022